Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.57 |
| ▸ | ITGAV | P06756 | 1/20 | 0.57 |
| ▸ | MME | P08473 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | CPA1 | P15085 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996293 | 1.00 | L3MBTL1 (0.58) | L3MBTL1ITGB3ITGAVMMECTSL | |
| SCHEMBL996291 | 1.00 | L3MBTL1 (0.58) | L3MBTL1ITGB3ITGAVMMECTSL | |
| Hydrochloric Acid SCHEMBL27371193 | 0.98 | L3MBTL1 (0.57) | L3MBTL1ITGB3ITGAVMMECTSL | |
| Hydrochloric Acid SCHEMBL28046933 | 0.98 | L3MBTL1 (0.57) | L3MBTL1ITGB3ITGAVMMECTSL | |
| SCHEMBL10964365 | 0.91 | MMP8 (0.56) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL7291638 | 0.89 | ITGB3 (0.54) | L3MBTL1ITGB3ITGAVCTSLCTSB | |
| SCHEMBL8244008 | 0.89 | ALDH1A1 (0.59) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL7460396 | 0.89 | POLB (0.64) | L3MBTL1ALDH1A1ALOX15 | |
| SCHEMBL10801015 | 0.88 | CTSL (0.54) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL15219608 | 0.88 | CTSL (0.52) | CTSLCTSBCTSSCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105541633-B | open-chain chiral crown ether containing ent-Bayesian skeleton and preparation and application thereof | 浙江工业大学 | 2017-05-17 | — | — | CN | disclosed |
| EP-2655322-A1 | PROCESS FOR PREPARING CHIRAL AMINO ACIDS | Diverchim (FR) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085474-A1 | PROCESS FOR PREPARING CHIRAL AMINO ACIDS | DIVERCHIM (FR) | 2012-06-28 | — | — | WO | disclosed |
| US-20100324058-A1 | THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | OBSCHESTVO S ORGANICHENNOI OTVETSTTVENNOCTIYOU "BIONIKA" (RU) | 2010-12-23 | — | — | US | disclosed |
| US-20060111553-A1 | Novel thrombin inhibitors, the preparation and use thereof | ABBOTT GMBH & CO. KG (DE) | 2006-05-25 | — | — | US | disclosed |
| EP-0773955-B1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | BASF AG (DE) | 2003-04-16 | — | — | EP | disclosed |
| US-20030004308-A1 | Novel thrombin inhibitors, the preparation and use thereof | BOHM HANS-JOACHIM (DE) | 2003-01-02 | — | — | US | disclosed |
| US-6455671-B1 | COMPOUND FOR USE IN THE TREATMENT OF THROMBOSIS | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
| EP-0922054-B1 | ANTICOAGULANT PEPTIDYL-ARGININE ALDEHYDE DERIVATIVES | GYOGYSZERKUTATO INTEZET (HU) | 2002-08-14 | — | — | EP | disclosed |
| US-6235707-B1 | Anticoagulant peptidyl-arginine aldehyde derivatives | GYOGYSZERKUTATO INTEZET KFT. (HU) | 2001-05-22 | — | — | US | disclosed |
| EP-0922054-A1 | ANTICOAGULANT PEPTIDYL-ARGININE ALDEHYDE DERIVATIVES | GYOGYSZERKUTATO INTEZET KFT. (HU) | 1999-06-16 | — | — | EP | disclosed |
| WO-1997046576-A1 | ANTICOAGULANT PEPTIDYL-ARGININE ALDEHYDE DERIVATIVES | Gyógyszerkutató Intézet Kft. (HU) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111553-A1 | Novel thrombin inhibitors, the preparation and use thereof | TFPI, F2, TFPI2 | L3MBTL1 3326/4885ITGB3 692/4885ITGAV 772/4885 |
| US-20100324058-A1 | THROMBIN FUNCTION COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS BASED ON THEM | F2, PLAT, SERPINC1 | L3MBTL1 4702/4885ITGB3 399/4885ITGAV 723/4885 |
| US-20030004308-A1 | Novel thrombin inhibitors, the preparation and use thereof | TFPI, SERPINC1, F2 | L3MBTL1 2943/4885ITGB3 741/4885ITGAV 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.